[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institute of Mental Health, Singapore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100370696","understanding-the-person-exploring-change-across-psychotherapies-100370696",false,"NCT04106713","Understanding the Person, Exploring Change Across Psychotherapies","Xchange","Inclusion Criteria:\n\n1. For patients:\n\n   1. 18-99 years old;\n   2. have current or past symptoms of anxiety and\u002For depression;\n   3. able to communicate and read in English;\n   4. able to provide informed consent.\n   5. Waitlist arm:\n\n      \\- Referred for psychotherapy but given a waiting time of 8 weeks or more to the first visit or not assigned to therapy at IMH.\n   6. Treatment as usual:\n\n      \\- Not assigned to any psychotherapeutic interventions.\n   7. iCBT: - Referred for iCBT;\n\n      \\- Identified as a 'P2' patient\u002Fappropriate for iCBT by triage.\n   8. Group therapy:\n\n      \\- Referred for group therapy;\n\n      \\- Identified as a 'P2' patient\u002Fappropriate for group therapy by triage.\n   9. Individual psychotherapy:\n\n      * Referred for individual therapy;\n      * Patient and therapist committed to frequent therapy (ideally fortnightly).\n2. For therapists:\n\n   1. Therapists who will see OR have been assigned to clients in the waitlist arm, iCBT, group therapy (e.g. PsychUp), and individual psychotherapy group.\n\nExclusion Criteria:\n\n1\\. For patients:\n\n1. current active suicidal intention or plan;\n2. cognitively-impaired\u002Fare unable to consent\u002Flack capacity to consent.","ALL","18 Years","99 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","Identifying predictors and understanding mechanisms of change will inform referral to psychotherapy, triage and right-siting by helping clinicians to understand how their patients are likely to benefit from clinical interventions. This study will be the first of its kind conducted in an Asian hospital setting to identify the predictors of response to individual, group and internet-delivered CBT for the treatment of depressed and anxious patients in the Institute of Mental Health (IMH), Singapore. With increasing challenges with hospital workload, there is an increasing emphasis on group and online interventions. Understanding of the factors that may predict outcome from these therapies can improve right-siting by identifying who will get better without therapy or who may not benefit from a given form of therapy and guide personalisation of care. An important biological predictor of outcome is likely to be genetic risk as it has been demonstrated that patients with greater melancholia and a family history may not be sufficiently treated with brief courses of therapy. Identifying psychological factors underlying psychological distress and determining the extent to which these factors are addressed by these interventions will help to improve and individualise existing psychotherapy and motivate new psychotherapeutic interventions.",[27,28],"Depression","Anxiety Disorders",[30,31,32,33],"Psychotherapy","Cognitive behavioural therapy","Group psychotherapy","Internet-based psychotherapy","RECRUITING","2026-08-05",{"date":37,"type":38},"2026-08-06","ACTUAL",{"date":40,"type":38},"2019-10-04",{"date":42,"type":21},"2026-09-30",{"name":44,"class":45},"Institute of Mental Health, Singapore","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100602020","a-pilot-study-to-examine-the-efficacy-of-internet-delivered-skills-training-in-affective-and-interpersonal-regulation-i-stair-for-individuals-with-adverse-childhood-experiences-and-subsyndromal-depression-100602020","NCT07118072","A Pilot Study to Examine the Efficacy of Internet-Delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) for Individuals With Adverse Childhood Experiences and Subsyndromal Depression","Internet-Delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) for Individuals With Adverse Childhood Experiences and Subsyndromal Depression: A Pilot Study","Inclusion Criteria:\n\n* Exposed to mild, moderate or severe adverse childhood experiences (ACEs)\n* Screened positive for subsyndromal depression\n* Singapore citizens or permanent residents (PRs)\n* Aged 21 years to 65 years\n* Able to speak and understand English\n* Willing and able to undergo intervention and assessment online\n\nExclusion Criteria:\n\n* Currently diagnosed with any mental disorder diagnoses;\n* Experience cognitive impairment as determined by attending physician\n* Have received or currently receiving dialectical behavior therapy (DBT) due to similarities with i-STAIR\n* Female participants who are pregnant","21 Years","65 Years",{"count":57,"type":21},150,[24],"The present study aims to pilot internet-delivered Skills Training in Affective and Interpersonal Regulation (i-STAIR) as a transdiagnostic emotion dysregulation intervention to prevent progression to depression in individuals with adverse childhood experiences (ACEs) and subsyndromal depression. The aims of the study are: (i) to examine the effectiveness of i-STAIR on emotion dysregulation, interpersonal skills, depressive and PTSD symptoms at post-intervention i.e. on completion of the intervention (8 weeks); (ii) to examine if gains were maintained at 3 month post- intervention follow-up.",[61],"Subthreshold Depression",[63,64,65,66,67,68,69],"skills training in affective and interpersonal regulation","emotion regulation","subthreshold depression","prevention intervention","digital intervention","transdiagnostic intervention","Singapore","2026-02-25",{"date":72,"type":38},"2026-02-27",{"date":74,"type":38},"2025-10-31",{"date":76,"type":21},"2028-12",{"name":44,"class":45},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100545693","a-novel-individualized-connectome-guided-approach-for-precision-intermittent-theta-burst-stimulation-for-depression-100545693","NCT06385223","A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression","A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression: a Double Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 21 years.\n2. DSM-5 diagnosis of current Major Depressive Episode.\n3. Montgomery-Asberg Depression Rating Scale score of 20 or more.\n4. Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication.\n5. Able to give informed consent.\n\nExclusion Criteria:\n\n1. DSM-5 psychotic disorder\n2. Drug or alcohol abuse or dependence (preceding 3 months).\n3. Rapid clinical response required, e.g., high suicide risk.\n4. Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy.\n5. Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device.\n6. Pregnancy.\n7. Unsuitable for MRI.",{"count":86,"type":21},70,[24],"The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.",[27],[91,92,93,94],"neuronavigated","iTBS","Accelerated","RCT","2024-07-30",{"date":97,"type":38},"2024-08-01",{"date":99,"type":38},"2024-07-01",{"date":101,"type":21},"2026-12-31",{"name":44,"class":45},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100543103","phase-3-an-open-label-single-arm-study-of-the-efficacy-of-accelerated-intermittent-theta-burst-stimulation-in-schizophrenia-patients-with-persistent-negative-symptoms-100543103","NCT06351514","An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms","NOBLE-TMS","Inclusion Criteria:\n\n1. Age ≥21 and ≤65 years;\n2. With primary diagnosis of schizophrenia or schizoaffective disorder;\n3. Patients experienced prominent and persistent negative symptoms \\[Scale for the Assessment of Negative Symptoms (SANS) score ≥3 or Positive and Negative Symptoms Scale (PANSS)- negative subscale score ≥20\\] in past 6 months;\n4. No clinically significant positive symptoms \\[PANSS positive subscale score \\\u003C20\\];\n5. No clinically significant depressive symptoms \\[Calgary Depression Scale for Schizophrenia (CDSS) score subscale \\\u003C12\\];\n6. Able to give consent.\n\nExclusion Criteria:\n\n1. With current misuse of or dependence on illegal drugs or alcohol;\n2. High Suicide risk;\n3. History of epileptic seizures;\n4. With severe brain trauma, injury or other neurological diseases;\n5. Metal (implants) in the skull;\n6. Pregnancy",{"count":111,"type":21},40,[113],"PHASE3","Schizophrenia patients commonly present with persistent negative symptoms which remain the main reason for dysfunction after recovery from an acute episode of psychotic symptoms. Negative symptoms in schizophrenia exact significant burden with no effective pharmacological or behavior treatment options thus far. Neuromodulatory modalities present a novel and alternative treatment approach and recent trials have shown preliminary evidence for the efficacy of intermittent Theta Burst Stimulation (iTBS) to treat negative symptoms in schizophrenia. In this study, we aim to examine the effectiveness of an accelerated iTBS treatment protocol as an augmentation treatment regime for patient in rehabilitation care with persistent negative symptoms.\n\nWe propose a pragmatic, open label and single arm clinical trial. Forty patients with diagnosis of schizophrenia, who had been stabilized from psychotic symptoms and currently suffering from dominant negative symptoms will be recruited and undergo accelerated iTBS treatment for 5 consecutive sessions each day for 5 working days. Participants will be followed up immediately, 1 month and 3 months after the end of treatment. Clinical assessment includes, BNSS, The Brief Negative Symptom Scale; SANS, Scale for the assessment of negative symptoms; SAPS, Scale for the assessment of positive symptoms; PANSS, Positive and Negative Symptoms Scale; MoCA, Montreal Cognitive Assessment scale; CDSS, Calgary Depression Scale for Schizophrenia: SDS, Sheehans' disability scale and EQ-5D. The primary endpoint of the trial is the change of negative symptoms as assessed by PANSS, negative symptoms subscale immediately after the treatment.\n\nThis study will determine whether accelerated iTBS is effective to be delivered as an augmentation therapy for patients with persistent negative symptoms. The optimal treatment system for this population can be immediately translated to clinical practice and benefit patients in need.",[116],"Schizophrenia; Negative Type","2024-04-02",{"date":119,"type":38},"2024-04-08",{"date":121,"type":38},"2024-04-01",{"date":123,"type":21},"2026-09",{"name":44,"class":45},""]